MINIMED INC (MMED)
Health Care · Medical Devices / Diabetes Technology · NASDAQ
MiniMed is a dedicated diabetes technology company providing automated insulin delivery and smart injection systems to improve glycemic control for patients worldwide.
What MINIMED INC does
MiniMed is a global medical technology company that develops, manufactures, and markets a suite of diabetes management solutions, including automated insulin delivery (AID) systems and smart multiple daily injection (Smart MDI) systems. The company's products integrate insulin delivery, glucose sensing, and proprietary dosing algorithms to improve glycemic outcomes for people with diabetes. Formerly the diabetes business of Medtronic, the company transitioned to a standalone public entity in March 2026.
Recent developments
In its fiscal Q1 2027, the company reported strong revenue growth, raised its organic revenue growth guidance to 10.5%, and achieved key pipeline milestones, including U.S. FDA submission for its MiniMed Fit patch pump and CE Mark approval for the MiniMed Flex. Additionally, the company expanded its partnership with Abbott Laboratories to integrate dual glucose-ketone sensors into its systems.
From MINIMED INC's filing of 2026-09-08.
Themes: automated insulin delivery (AID), diabetes management, CGM / glucose sensing, Smart MDI / connected insulin pens, digital health, medtech spinoff
Fundamentals
- Price$19.80 as of 2026-10-08 close
- Market cap$5.6B as of 2026-09-03 (share count; price 2026-10-08)
- P/En/a negative earnings
- Net margin-10.7% FY2026, SEC XBRL
- Gross margin+54.2% FY2026, SEC XBRL
- ROE-9.2% FY2026, SEC XBRL
- Debt / equity0.00 as of 2026-09-03
- Revenue growth (YoY)+14.3% FY2026 vs FY2025, SEC XBRL
- Revenue CAGR (3y)+12.1% SEC XBRL
- Beta0.84 as of 2026-09-03
- Last reported earnings2026-09-01 SEC EDGAR Form 8-K (Item 2.02)
How MMED compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 10% 494 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
MMED is not currently in any published Top 10 list. Its scores are below.
Top 10 score
46.8 #917 of 1,379 scored · #110 of 151 in Health Care
Valuation 81st (price to book 1.5) and growth 69th (3-year revenue CAGR 12.1%); weakest is profitability (10th, return on equity -9.2%, operating margin -6.1%).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
How MINIMED INC looks technically
MINIMED INC (MMED): a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 2 trading days ago. Trading volume is running unusually high — about 5.9× its 30-day average, a sign of heightened interest.
Trend
8
| Distance from the 200-day | not enough price history yet — needs 200 trading sessions | n/a |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $20.50 | $20.50 |
| 200-day moving average | not enough price history yet — needs 200 trading sessions | n/a |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 36 calendar days ago — the swings before that are what the structure reading is measured on | 36 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 15.69. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible upward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | not enough price history yet — needs 200 trading sessions | n/a |
| Trend strength (14-day ADX) | a trend is forming but not yet strong — ADX, a 0–100 trend-strength gauge, is 22 (a reading of 25+ marks a strong trend) | 21.8 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 45, neither overbought (above 70) nor oversold (below 30) | 44.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($18.94 to $22.30) — its "stochastic" reading is 26 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 25.6 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 19 sessions |
Range
7
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
|---|---|---|
| Since a 55-day breakout | it made a new 55-day high about 25 trading days ago | 25 sessions |
| All-time high | its highest closing price on record is $24.43 (set on 2026-09-02) | $24.43 |
| Given back of the 52-week move | not available for this company yet | n/a |
| Nearest price level | not enough price history yet — needs 252 trading sessions | n/a |
| All-time low | its lowest closing price on record is $10.65 (set on 2026-05-15) | $10.65 |
| Above the all-time low | it is 85.9% above its all-time low | +85.9% |
Volatility
4
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 80% of it) | 20th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.8736 between its high and its low — about 4.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.8736 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $18.58 and $22.82 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $18.58 – $20.70 – $22.82 |
| Typical daily range (% of price) | its price moves about 4.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.4% |
Volume
1
| Volume vs its 30-day average | trading volume is running unusually high — about 5.9× its 30-day average, a sign of heightened interest | 5.88× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a hammer | 5 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 5 sessions ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 2.4% above the previous close 47 sessions ago and has not traded back through the level it left behind at 18.05 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.4% |
| Gap filled | a 2.6% gap up opened on 2026-09-22 has been "filled" 12 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 12 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 16.1 percentage points (the stock lost 15.1% while the market gained 1.0%) | -16.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 28.0 percentage points (the stock gained 31.8% while the market gained 3.8%) | +28.0% |
| vs market, 6 months | over the past 6 months this stock beat the market by 32.2 percentage points (the stock gained 49.7% while the market gained 17.5%) | +32.2% |
| vs market, 12 months | not available for this company yet | n/a |
Signal agreement
2
| Bullish technical signals | 1 of the 7 technical signals we can compute for it is currently in a bullish state: outperforming the market over 6 months — these describe past price behaviour, not a forecast | 1 of 7 |
|---|---|---|
| Bearish technical signals | 2 of the 7 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative — these describe past price behaviour, not a forecast | 2 of 7 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 11.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 7% above the average price paid since 2026-03-06, so the typical buyer over that stretch is showing a gain. That average is $18.52 — a volume-weighted average of daily closes over 140 sessions, not a true tick-by-tick VWAP. | +6.9% |
|---|---|---|
| Vs the average paid since it last reported | the price is 4% below the average price paid since it last reported on 2026-09-01 (its 8-K), so the typical buyer over that stretch is under water. That average is $20.68 — a volume-weighted average of daily closes over 27 sessions, not a true tick-by-tick VWAP. | -4.2% |
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $15.69.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $19.57 and $22.13 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This reading has stood for 35 trading days, since 2026-08-20.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Unusually heavy trading volume · Broke down to a new 20-day low · Printed a bullish engulfing pair · Under water since its last earnings report (below the anchored VWAP) · Trading inside the Ichimoku cloud · Elliott wave 4 pullbacks | Learn: adx · rsi · breakout · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.46 mean, 1=Strong Buy…5=Strong Sell) — 12 analysts
- Mean price target$24.92 range $15.00 – $29.00; median $26.00
Analyst estimates, as of 2026-10-03. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MMED
- Consensus EPS estimate$0.123 next reporting period, as of 2026-10-03
- Readings revised upward25% of 4 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Intensifying competition and pricing pressure in the CGM market.","Risks associated with the transition from a subsidiary of Medtronic to a standalone public company.","Fluctuations in costs for raw materials, logistics, and labor, alongside potential reimbursement challenges."]
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for MMED — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding MMED as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 9,373,573
- Reported value $140,134,917
reported quarterly holdings change (2026-03-31 → 2026-06-30): 2 new, 2 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about MMED's institutional holders → See what each manager we track holds →
Short interest (FINRA)
MMED had 13,594,922 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
MMED had 4.83% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.85 days to cover at the same settlement.
- Reported short interest (shares) 13,594,922
- Short interest (% of shares outstanding) 4.83%
- Prior settlement (shares) 8,060,409
- Reported change 68.66%
- Days to cover (reported) 4.85
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MMED vs…
MINIMED INC is found in…
MMED shows up in…
Frequently asked questions
What does MINIMED INC (MMED) do?
MiniMed is a global medical technology company that develops, manufactures, and markets a suite of diabetes management solutions, including automated insulin delivery (AID) systems and smart multiple daily injection (Smart MDI) systems. The company's products integrate insulin delivery, glucose sensing, and proprietary dosing algorithms to improve glycemic outcomes for people with diabetes.
What sector is MINIMED INC (MMED) in?
MINIMED INC (MMED) is classified in the Health Care sector. Its industry is Medical Devices / Diabetes Technology. It trades on NASDAQ.
Who are MINIMED INC's (MMED) competitors?
Notable peers of MINIMED INC (MMED) include DexCom, Insulet, Tandem Diabetes Care, Abbott Laboratories and Roche. This peer set is informational only — not financial advice.
Is MINIMED INC (MMED) overbought or oversold right now?
MINIMED INC (MMED) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 45, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MMED come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.